Urinary RNA Assay May Replace Needle Biopsy for Detection of Kidney Transplant Rejection
By LabMedica International staff writers Posted on 17 Mar 2014 |
Determination of mRNA signatures in urine samples may replace needle biopsy for diagnosing kidney dysfunction following transplant surgery.
Investigators at Weill Cornell Medical College (New York, NY, USA) measured absolute levels of 26 pre-specified mRNAs in urine samples collected from kidney graft recipients at the time of needle biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction would be feasible using urinary cell mRNA profiles. They profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell–mediated rejections and 26 acute antibody-mediated rejections) and 32 urine samples from 32 patients with acute tubular injury without acute rejection.
Results of stepwise discriminant mRNA analysis identified a linear combination of mRNAs for CD3epsilon, CD105, TLR4, CD14, complement factor B, and vimentin that distinguished acute rejection from acute tubular injury. Among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3epsilon, CD105, CD14, CD46, and 18S rRNA that distinguished T cell–mediated rejection from antibody-mediated rejection.
“Using statistical methods we have combined the mRNAs to yield a diagnostic signature,” said senior author Dr. Thangamani Muthukumar, assistant professor of medicine at Weill Cornell Medical College. “Our study shows that when the creatinine level is elevated in the blood of a kidney transplant recipient, use of our urine test would differentiate the common causes of kidney dysfunction that led to the elevation in creatinine, hence benefiting many patients by allowing them to avoid the need for an invasive needle biopsy.”
The study showing the correspondence between mRNA signatures and needle biopsy results was published in the March 7, 2014, online edition of the Journal of the American Society of Nephrology.
Related Links:
Weill Cornell Medical College
Investigators at Weill Cornell Medical College (New York, NY, USA) measured absolute levels of 26 pre-specified mRNAs in urine samples collected from kidney graft recipients at the time of needle biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction would be feasible using urinary cell mRNA profiles. They profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell–mediated rejections and 26 acute antibody-mediated rejections) and 32 urine samples from 32 patients with acute tubular injury without acute rejection.
Results of stepwise discriminant mRNA analysis identified a linear combination of mRNAs for CD3epsilon, CD105, TLR4, CD14, complement factor B, and vimentin that distinguished acute rejection from acute tubular injury. Among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3epsilon, CD105, CD14, CD46, and 18S rRNA that distinguished T cell–mediated rejection from antibody-mediated rejection.
“Using statistical methods we have combined the mRNAs to yield a diagnostic signature,” said senior author Dr. Thangamani Muthukumar, assistant professor of medicine at Weill Cornell Medical College. “Our study shows that when the creatinine level is elevated in the blood of a kidney transplant recipient, use of our urine test would differentiate the common causes of kidney dysfunction that led to the elevation in creatinine, hence benefiting many patients by allowing them to avoid the need for an invasive needle biopsy.”
The study showing the correspondence between mRNA signatures and needle biopsy results was published in the March 7, 2014, online edition of the Journal of the American Society of Nephrology.
Related Links:
Weill Cornell Medical College
Latest Pathology News
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy